Neurologic Drugs : Parkinsonism
TNEUP1 “Neupro transdermal patch 6mg/24h”
Each Transdermal Patch (30cm2) contain 13.5 mg
適應症：原發性帕金森氏症。
Usual dose:
Parkinson’s disease:
Early-stage: Initial, 2 mg/24 hours TRANSDERMALLY; titration, 2 mg/24 hours TRANSDERMALLY weekly; minimum effective dose, 4 mg/24 hours TRANSDERMALLY; MAX, 6 mg/24 hours TRANSDERMALLY
Advanced-stage: Initial, 4 mg/24 hours TRANSDERMALLY; titration, 2 mg/24 hours TRANSDERMALLY weekly; MAX, 8 mg/24 hours TRANSDERMALLY
Restless legs syndrome (Moderate to Severe)
Initial, 1 mg/24 hours transdermally; titration, 1 mg/24 hours transdermally weekly; minimum effective dose, 1 mg/24 hours transdermally; max, 3 mg/24 hours transdermally.
Adverse effect:
Common: Orthostatic hypotension, peripheral edema, Application site reaction, diaphoresis, loss of appetite, nausea, vomiting, xerostomia, dizziness, dyskinesia, headache, somnolence.
Serious: Atrioventricular block, first degree; syncope, sleep attack, compulsive behavior, hallucinations, impulse control disorder.
健保使用規範：Rotigotine貼片劑（如Neupro Patch），限用於原發性帕金森氏症，每日限用一片，且不得併用其他dopamine agonist之口服藥品(100/6/1)。